Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972256 | 0.87 | CA2 (0.32) | CA2 | |
| SCHEMBL11972262 | 0.87 | CA2 (0.32) | CA2 | |
| SCHEMBL19897347 | 0.84 | CYP24A1 (0.34) | CYP24A1CA2ATML3MBTL1 | |
| SCHEMBL15260634 | 0.84 | AOC3 (0.38) | CA2CA12CA1CA9 | |
| SCHEMBL22264312 | 0.84 | APLNR (0.34) | CA2CA12CA1CA9 | |
| SCHEMBL15260635 | 0.84 | AOC3 (0.38) | CA2CA12CA1CA9 | |
| SCHEMBL22264315 | 0.84 | APLNR (0.34) | CA2CA12CA1CA9 | |
| SCHEMBL22264292 | 0.84 | AOC3 (0.38) | CA2 | |
| SCHEMBL15261181 | 0.84 | AOC3 (0.38) | CA2 | |
| SCHEMBL15261182 | 0.84 | AOC3 (0.38) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| EP-0665223-A1 | Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | PDK1, PDK2, PDK3 | CYP24A1 2362/4885CA2 1163/4885ATM 370/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP24A1 3687/4885CA2 2065/4885ATM 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.